Genetic Mutations Associated with Breast Cancer in Pakistan
DOI:
https://doi.org/10.18034/mjmbr.v4i2.439Keywords:
Breast Cancer, Genetic Mutation, Cell Cycle RegulationAbstract
Breast cancer is the most common malignancy in women worldwide. Various environmental and genetic factors are involved in breast carcinogenesis. Mutations in autosomal dominant genes account for 5-10% of breast cancer cases. It is also the most common female malignancy in Pakistan and account for 35.6% of all cancers in women. BRCA1 and BRCA2 are the key genes associated with familial and early-onset breast cancer in Pakistan. However, mutation in TP53, RAD51 and CHEK2 genes play the marginal role. In this review, the spectrums of genetic mutations associated with breast cancer in Pakistan are discussed in detail.
Downloads
References
Afsharfard, A., Mozaffar, M., Orang, E., & Tahmasbpour, E. (2013). Trends in Epidemiology, Clinical and Histopathological Characteristics of Breast Cancer in Iran : Results of a 17 Year Study. Asian Pacific Journal of Cancer Prevention, 14(11). 6905-6911.
Amir, E., Freedman, O. C., Seruga, B., Evans, D. G. (2010). Assessing women at high risk of breast cancer: a review of risk assessment models. JNatl Cancer Inst. 102:680–691
Bartek, J., Lukas, J.(2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3:421–429.
Berclaz, G., Li, S., Price, K.N., Coates, A.S., Castiglione, G. M., Rudenstam, C. M., Holmberg, S. B. (2004). Body mass index as a prognostic feature inoperable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol, 15(6):875–884
Bhurgri, Y. (2004). Karachi cancer registry data–implications for the national cancer control programe of Pakistan.Asian Pacific J Cancer Prev 5, 77-82.
Buisson, R., Niraj, J., Pauty, J., Maity, R., Zhao, W., Coulombe, Y., … Masson, J.-Y. (2014). Breast cancer proteins PALB2 and BRCA2 stimulate polymerase η in recombination-associated DNA synthesis at blocked replication forks. Cell Reports, 6(3), 553–64.
Chapman, M. S., & Verma, I. M. (1996). Transcriptional activation by BRCA1. Nature, 382(6593), 678–9.
Chaturvedi, P., Eng, W. K., Zhu, Y., Mattern, M. R., Mishra, R., Hurle, M. R., … Zhou, B. B. (1999). Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene, 18(28), 4047–54.
Chehab, N. H., Malikzay, A., Appel, M., & Halazonetis, T. D. (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes & Development, 14(3), 278–88.
Cheung, K. L. (2007). Endocrine therapy for breast cancer: an overview. Breast, 16 (4):327–343.
Clark, S. L., Rodriguez, A. M., Snyder, R. R., Hankins, G. D. V, & Boehning, D. (2012). Structure-Function Of The Tumor Suppressor BRCA1. Computational and Structural Biotechnology Journal, 1(1). http://doi.org/10.5936/csbj.201204005
Collins, J. S., Perry, R. T., Watson, B., Harrell, L. E., Acton, R. T., Blacker, D., … Go, R. C. (2000). Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. American Journal of Medical Genetics, 96(6), 823–30
Conway, A. B., Lynch, T. W., Zhang, Y., Fortin, G. S., Fung, C. W., Symington, L. S., & Rice, P. A. (2004). Crystal structure of a Rad51 filament. Nature Structural & Molecular Biology, 11(8), 791–6.
Cybulski, C., Gorski, B., Huzarski, T., Masojc, B., Mierzejewski, M., Debniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al(2004). CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet, 75:1131–1135.
Davies, O. R., & Pellegrini, L. (2007). Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nature Structural & Molecular Biology, 14(6), 475–83.
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001). The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature, 410(6830), 842–7.
Hankinson, S. E. (2008). Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer. Adv Exp Med Biol, 617:161–169
Kakarala, M., Rozek, L., Cote, M., Liyanage, S., Brenner, D. E. (2010). Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US–a SEER analysis. BMC Cancer 10:191.
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science (New York, N.Y.), 252(5013), 1708–11
Kim, H., & Choi, D. H. (2013). Distribution of BRCA1 and BRCA2 mutations in Asian patients with breast cancer. Journal of Breast Cancer, 16(4), 357–365.
Lee, J. S., Collins, K. M., Brown, A. L., Lee, C. H., Chung, J. H.(2000) hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature, 404:201–204.
Li, F. P., Fraumeni, J. F. Mulvihill, J.J et al., (1988). A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362.
Liede, A., Malik, I. A., Aziz, Z., Delos, Rios, P., Kwan, E., Narod, S.A. (2002). Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. American Journal of Human Genetics, vol. 71(3): 595–606.
Liu, Y., Liao, J., Xu, Y., Chen,W., Liu, D., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., et al., (2011). A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women. Hum Mutat, 32:1000–1003.
Loman, N., Johannsson, O., Bendahl, P. O., et al., (1998). Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 83, 310-9.
Majeed, W., Bilal, A., Ijaz, J., Tanweer, K., Faqir, M., Asghar, A., Ahmad, R. (2014). Breast Cancer: Major Risk Factors and Recent Developments in Treatment. Asian Pacific Journal of Cancer Prevention 15 (8), 3353-3358.
Malik, F. A., Ashraf, S., Kayani, A., Jiang, W. G, Mir, A., Ansar, M. (2008). Contribution of BRCA1 germline mutation in patients with sporadic breast cancer. International Seminars in Surgical Oncology, vol. 5, published online.
Malkin, D., Li, F.P., Strong, L. C. et al., (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238.
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., Elledge, S. J. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA, 97:10389–10394.
Manié, E., Vincent-Salomon, A., Lehmann-Che, J., Pierron, G., Turpin, E., Warcoin, M., … Stern, M.-H. (2009). High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Research, 69(2), 663–71.
McCoy, M. L., Mueller, C. R., & Roskelley, C. D. (2003). The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reproductive Biology and Endocrinology : RB&E, 1, 72.
Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., … Hanenberg, H. (2010). Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature Genetics, 42(5), 410–4.
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P., Harshman, K., Tavtigian, S., … et, al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266(5182), 66–71.
Mizuta, R., LaSalle, J. M., Cheng, H. L., Shinohara, A., Ogawa, H., Copeland, N., … Alt, F. W. (1997). RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proceedings of the National Academy of Sciences of the United States of America, 94(13), 6927–32
Moatter, T., Aban, M., Khan, S., Azam, I., & Pervez, S. (2011). BRCA1 status in Pakistani breast cancer patients with moderate family history. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 21(11), 680–4.
Moran, M. S., Gonsalves, L., Goss, D. M., Ma, S. (2011). Breast cancers in U.S. residing Indian-Pakistani versus non-Hispanic White women: comparative analysis of clinical-pathologic features, treatment, and survival. Breast Cancer Res Treat 128:543–551.
Pimhanam C., Sangrajrang, S., Ekpanyaskul, C. (2014). Tobacco Smoke Exposure and Breast Cancer Risk in Thai Urban Females. Asian Pacific Journal of Cancer Prevention, Vol 15, 2014, 15, 7407–7411.
Rashid, M. U., Gull, S., Asghar, K., Muhammad, N., Amin, A., & Hamann, U. (2012). Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. Familial Cancer, 11(2), 307–311.
Rashid, M. U., Zaidi, A., Torres, D., Sultan, F., Benner, A., Naqvi, B., … Hamann, U. (2006). Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. International Journal of Cancer. Journal International Du Cancer, 119(12), 2832–2839.
Rashid, M. U., Muhammad, N., Faisal, S., Amin, A., & Hamann, U. (2014). Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan. Breast Cancer Research and Treatment, 145(3), 775–784.
Rodriguez, M. C and Songyang, Z.(2008). BRCT domains: Phosphopeptide bonding and signaling models. Front Biosci 13.5904-5915.
Sheikh, A., Hussain, S. A., Ghori, Q., Naeem, N., Giri, S., Sathian, B., … Tamimi, D. M. Al. (2015). The Spectrum of Genetic Mutations in Breast Cancer. Asian Pacific Journal of Cancer Prevention, Vol 15, 2014, 16, 2177–2185.
Shuen, A. Y., & Foulkes, W. D. (2011). Inherited mutations in breast cancer genes--risk and response. Journal of Mammary Gland Biology and Neoplasia, 16(1), 3–15.
Silwal-Pandit, L., Vollan, H. K. M., Chin, S.-F., Rueda, O. M., McKinney, S., Osako, T., … Langerød, A. (2014). TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 20(13), 3569–80.
Silva, I. S., De-Stavola, B., McCormack, V. (2008). Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. PLoS Med. doi: 10.1371/journal.pmed.0050193.
Thun, M. J., DeLancey, J. O., Center, M. M., Jemal, A., & Ward, E. M. (2009). The global burden of cancer: Priorities for prevention. Carcinogenesis, 31(1), 100–110.
Toh, S., Mitchell, A. A., Werler, M. M., & Hernandez-Diaz, S. (2007). Toh et al. Respond to “Compromise or Compromising?” American Journal of Epidemiology, 167(6), 644–645.
Vahteristo, P., Bartkova, J., Eerola, H., Syrjakoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomaki, K., Heikkila, P., et al., (2002), A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet, 71:432–438.
Vander, G. P., vander, W. E., van Diest, P. J. (2011). Pathology of hereditary breast cancer. Cell Oncol (Dordr), 34, 71-88.
Varley, J. M. (2003). Germline TP53 mutations and Li-Fraumeni syndrome. Human Mutation, 21(3), 313–20. http://doi.org/10.1002/humu.10185
Vaz, F., Hanenberg, H., Schuster, B., Barker, K., Wiek, C., Erven, V., … Mathew, C. G. (2010). Mutation of the RAD51C gene in a Fanconi anemia–like disorder. Nature Genetics, 42(5),
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., … King, M.-C. (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 107(28), 12629–33.
Warner, E., Hill, K., Causer, P., Plewes, D., Jong, R., Yaffe, M., … Narod, S. A. (2011). Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 29(13), 1664–9.
Weischer, M., Bojesen, S. E., Ellervik, C., Tybjaerg,H. A., Nordestgaard, B. G. ( 2008). CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol, 26:542–548.
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., … Micklem, G. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559), 789–92.
Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., … Livingston, D. M. (2006). Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Molecular Cell, 22(6), 719–29.
Zaman, K., Bodmer, A., Pralong, F., Castiglione, G. M. (2012). Breast cancer and obesity, a dangerous relation. Rev Med Suisse, 8(342):1101–1104..
Zeng, Y., Forbes, K. C., Wu, Z., Moreno, S., Piwnica, W. H., Enoch, T.(1998) Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature, 395:507–510.
Zhang, S., Phelan, C. M., Zhang, P., Rousseau, F., Ghadirian, P., Robidoux, A., Foulkes, W., Hamel, N., McCready, D., Trudeau, M., et al., (2008). Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Cancer Res 68:2154–2157.
-- 0 --
